 |
96 Diseases |  |
29 Trials |
|
29 Trials |  |
1185 News |  |
| «12...45678910111213141516» |
- | lomustine / Generic mfg., temozolomide / Generic mfg.
Trial completion, Trial primary completion date, Combination therapy: CeTeG: Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients (clinicaltrials.gov) - Jun 14, 2017
P3, N=141, Completed, Sponsor: University Hospital, Bonn
Active, not recruiting --> Completed | Trial primary completion date: Nov 2015 --> Apr 2017
- | Recentin (cediranib) / AstraZeneca, Avastin (bevacizumab) / Roche
Review, Journal: Angiogenesis inhibitors in tackling recurrent glioblastoma. (Pubmed Central) - Jun 7, 2017
Besides reoperation and occasionally reirradiation, systemic treatment of recurrent glioblastoma consists of alkylating chemotherapy (lomustine, temozolomide), bevacizumab and combinations thereof...Expert commentary: New insights in glioma neoangiogenesis, increasing understanding of vascular pathway escape mechanisms, and upcoming immunotherapy approaches might revitalize the therapeutic potential of antiangiogenic agents against glioblastoma, although with a different treatment intention. The combination of antiangiogenic approaches with or without radiotherapy might still hold promise to complement the therapeutic armamentarium of fighting glioblastoma.
- || Inlyta (axitinib) / Pfizer
Trial primary completion date, Combination therapy, Monotherapy: AxiGII: A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma (clinicaltrials.gov) - May 24, 2017
P2, N=52, Active, not recruiting, Sponsor: Bart Neyns
The combination of antiangiogenic approaches with or without radiotherapy might still hold promise to complement the therapeutic armamentarium of fighting glioblastoma. Trial primary completion date: Dec 2016 --> Dec 2017
- |||||||||| dianhydrogalactitol (VAL-083) / Valent Tech
New P3 trial: STAR-3: VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM (clinicaltrials.gov) - May 10, 2017
P3, N=180, Not yet recruiting, Sponsor: DelMar Pharmaceuticals, Inc.
- | Sutent (sunitinib) / Pfizer
Trial initiation date: STELLAR: A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - May 8, 2017
P2/3, N=100, Not yet recruiting, Sponsor: VU University Medical Center
Trial primary completion date: Dec 2016 --> Dec 2017 Initiation date: Mar 2017 --> Jun 2017
- | Matulane (procarbazine hydrochloride) / Leadiant Biosci
Trial completion: Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma (clinicaltrials.gov) - Apr 20, 2017
P2, N=1, Completed, Sponsor: OHSU Knight Cancer Institute
Initiation date: Mar 2017 --> Jun 2017 Active, not recruiting --> Completed
- | lomustine / Generic mfg., carmustine / Generic mfg.
Journal: Analysis of Risk Factors for Abnormal Pulmonary Function in Pediatric Cancer Survivors. (Pubmed Central) - Mar 19, 2017
Almost two-thirds of survivors screened per the COG-LTFU Guidelines had an abnormal PFT but a majority reported no clinical symptoms. Hyperinflation was the most prevalent abnormality.
- | NN1213 / Novo Nordisk
Trial primary completion date, Surgery: Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma (clinicaltrials.gov) - Mar 14, 2017
P=N/A, N=6, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Hyperinflation was the most prevalent abnormality. Trial primary completion date: Feb 2017 --> Feb 2018
- ||||| vocimagene amiretrorepvec/extended release flucytosine (DB107) / Denovo
Enrollment closed: Toca5: The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma (clinicaltrials.gov) - Feb 9, 2017
P2/3, N=187, Active, not recruiting, Sponsor: Tocagen Inc.
Trial primary completion date: Feb 2017 --> Feb 2018 Recruiting --> Active, not recruiting
- || Sutent (sunitinib) / Pfizer
New P2/3 trial: STELLAR: A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - Jan 23, 2017
P2/3, N=100, Not yet recruiting, Sponsor: VU University Medical Center
- | disulfiram / Generic mfg.
Enrollment open: Disulfiram in Recurrent Glioblastoma (clinicaltrials.gov) - Jan 18, 2017
P2/3, N=142, Recruiting, Sponsor: Sahlgrenska University Hospital, Sweden
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | lomustine / Generic mfg.
New P2 trial: Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma (clinicaltrials.gov) - Jan 17, 2017
P2, N=37, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- |||| depatuxizumab mafodotin (ABT-414) / AbbVie
Enrollment open, Trial primary completion date: RTOG Foundation 3508: Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas (clinicaltrials.gov) - Nov 2, 2016
P2, N=260, Recruiting, Sponsor: AbbVie
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting | Trial primary completion date: Jun 2017 --> Dec 2019
- Avastin (bevacizumab) / Roche
Trial completion, Trial primary completion date: Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM) (clinicaltrials.gov) - Oct 31, 2016
P2, N=83, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Recruiting | Trial primary completion date: Jun 2017 --> Dec 2019 Active, not recruiting --> Completed | Trial primary completion date: Feb 2018 --> Oct 2016
- | disulfiram / Generic mfg.
Phase classification, Trial initiation date, Trial primary completion date: Disulfiram in Recurrent Glioblastoma (clinicaltrials.gov) - Oct 14, 2016
P2/3, N=142, Not yet recruiting, Sponsor: Sahlgrenska University Hospital, Sweden
Active, not recruiting --> Completed | Trial primary completion date: Feb 2018 --> Oct 2016 Phase classification: P2 --> P2/3 | Initiation date: Sep 2016 --> Jan 2017 | Trial primary completion date: May 2019 --> Dec 2019
- |||| Matulane (procarbazine hydrochloride) / Leadiant Biosci
Enrollment open, Trial primary completion date: Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma (clinicaltrials.gov) - Sep 30, 2016
P2, N=90, Recruiting, Sponsor: AIDS Malignancy Consortium
Phase classification: P2 --> P2/3 | Initiation date: Sep 2016 --> Jan 2017 | Trial primary completion date: May 2019 --> Dec 2019 Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2017 --> Jan 2021
- |||||| eflornithine / Orbus Therap
Enrollment open: STELLAR: Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients (clinicaltrials.gov) - Sep 19, 2016
P3, N=280, Recruiting, Sponsor: Orbus Therapeutics, Inc.
Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2017 --> Jan 2021 Not yet recruiting --> Recruiting
- || Inlyta (axitinib) / Pfizer
Trial primary completion date, Combination therapy, Monotherapy: AxiGII: A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma (clinicaltrials.gov) - Sep 9, 2016
P2, N=52, Active, not recruiting, Sponsor: Bart Neyns
Not yet recruiting --> Recruiting Trial primary completion date: May 2015 --> Dec 2016
- |||| depatuxizumab mafodotin (ABT-414) / AbbVie
Enrollment open: RTOG Foundation 3508: Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas (clinicaltrials.gov) - Aug 16, 2016
P2, N=240, Recruiting, Sponsor: AbbVie
Trial primary completion date: May 2015 --> Dec 2016 Active, not recruiting --> Recruiting
- | buparlisib (AN2025) / Adlai Nortye
Trial completion: Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - Aug 10, 2016
P1/2, N=35, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Recruiting Active, not recruiting --> Completed
- ||| depatuxizumab mafodotin (ABT-414) / AbbVie
Enrollment closed: RTOG Foundation 3508: Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas (clinicaltrials.gov) - Jul 27, 2016
P2, N=240, Active, not recruiting, Sponsor: AbbVie
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche
New trial, Metastases: Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI (clinicaltrials.gov) - Jul 25, 2016
P=N/A, N=85, Not yet recruiting, Sponsor: Massachusetts General Hospital
- buparlisib (AN2025) / Adlai Nortye
Trial primary completion date: Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - Jul 19, 2016
P1/2, N=35, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2016 --> Aug 2016
- | NN1213 / Novo Nordisk, Matulane (procarbazine hydrochloride) / Leadiant Biosci
Trial completion: Chemotherapy Followed by Radiation Therapy in Treating Adults With Supratentorial Glioma (clinicaltrials.gov) - Jul 11, 2016
P2, N=43, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Apr 2016 --> Aug 2016 No longer recruiting --> Completed
- Avastin (bevacizumab) / Roche, Pravitinib (carboxyamidotriazole orotate) / Tactical Therap
Enrollment change, Trial termination, Trial primary completion date, Combination therapy: Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma (clinicaltrials.gov) - Jun 16, 2016
P1/2, N=9, Terminated, Sponsor: Annick Desjardins
No longer recruiting --> Completed N=138 --> 9 | Suspended --> Terminated | Trial primary completion date: Apr 2017 --> Mar 2015; This study was terminated early due to funding issues prior to completion of phase I
- ||| Matulane (procarbazine hydrochloride) / Leadiant Biosci
Trial initiation date, Trial primary completion date: Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jun 13, 2016
P2, N=90, Not yet recruiting, Sponsor: AIDS Malignancy Consortium
N=138 --> 9 | Suspended --> Terminated | Trial primary completion date: Apr 2017 --> Mar 2015; This study was terminated early due to funding issues prior to completion of phase I Initiation date: Dec 2015 --> Sep 2016 | Trial primary completion date: Dec 2017 --> Sep 2017
- || eflornithine / Orbus Therap
New P3 trial: STELLAR: Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients (clinicaltrials.gov) - Jun 11, 2016
P3, N=280, Not yet recruiting, Sponsor: Orbus Therapeutics, Inc.
- ||||| Avastin (bevacizumab) / Roche
Enrollment closed, Trial primary completion date: A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma (clinicaltrials.gov) - Jun 5, 2016
P3, N=299, Active, not recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Dec 2015 --> Sep 2016 | Trial primary completion date: Dec 2017 --> Sep 2017 Trial primary completion date: Mar 2017 --> Dec 2016 | Recruiting --> Active, not recruiting
- ||||||| NN1213 / Novo Nordisk
Trial completion, Combination therapy: Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma (clinicaltrials.gov) - May 19, 2016
P3, N=528, Completed, Sponsor: Children's Oncology Group
Trial primary completion date: Mar 2017 --> Dec 2016 | Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| USL311 / Sawai Pharma
New P1/2 trial, Combination therapy, Metastases: Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM) (clinicaltrials.gov) - May 6, 2016
P1/2, N=120, Recruiting, Sponsor: Upsher-Smith Laboratories
- Depocyte (liposomal cytarabine) / Mundipharma, Leadiant Biosci
Trial termination, Combination therapy: A Clinical Trial to Assess the Safety & Efficacy of the Treatment of Patients With Metastasis From Malignant Melanoma - Treatment Consists of the Substances Lomustine (Capsules) & Cytarabine (Injected Into an Area Near the Spinal Cord), Accompanied by Radiotherapy of the Brain (clinicaltrials.gov) - Apr 19, 2016
P1, N=1, Terminated, Sponsor: University Hospital, Bonn
Active, not recruiting --> Completed Recruiting --> Terminated; No patients can be recruited for this trial anymore due to other therapeutical approaches that became available.
- |||| NN1213 / Novo Nordisk
Trial primary completion date, Combination therapy: Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma (clinicaltrials.gov) - Apr 11, 2016
P3, N=549, Active, not recruiting, Sponsor: Children's Oncology Group
Recruiting --> Terminated; No patients can be recruited for this trial anymore due to other therapeutical approaches that became available. Trial primary completion date: Dec 2015 --> Mar 2016
- |||| NN1213 / Novo Nordisk
Trial primary completion date, Combination therapy: Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma (clinicaltrials.gov) - Apr 9, 2016
P3, N=549, Active, not recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Dec 2015 --> Mar 2016 Trial primary completion date: Jun 2016 --> Dec 2015
- ||||| Avastin (bevacizumab) / Roche
Enrollment closed: A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma (clinicaltrials.gov) - Apr 7, 2016
P3, N=299, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jun 2016 --> Dec 2015 Recruiting --> Active, not recruiting
- | New P2 trial: LEAHRN: Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma (clinicaltrials.gov) - Mar 31, 2016
P2, N=45, Not yet recruiting, Sponsor: Children's Oncology Group
- buparlisib (AN2025) / Adlai Nortye
Trial primary completion date: Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - Mar 8, 2016
P1/2, N=35, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> Apr 2016
- |||||| Avastin (bevacizumab) / Roche
Enrollment open: A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma (clinicaltrials.gov) - Mar 4, 2016
P3, N=298, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Dec 2015 --> Apr 2016 Active, not recruiting --> Recruiting
- |||| NN1213 / Novo Nordisk
Trial primary completion date, Combination therapy: Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma (clinicaltrials.gov) - Feb 10, 2016
P3, N=549, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Recruiting Trial primary completion date: Dec 2015 --> Jun 2016
- | disulfiram / Generic mfg.
New P2 trial: Disulfiram in Recurrent Glioblastoma (clinicaltrials.gov) - Feb 10, 2016
P2, N=142, Not yet recruiting, Sponsor: Sahlgrenska University Hospital, Sweden
- Avastin (bevacizumab) / Roche
Trial primary completion date: Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM) (clinicaltrials.gov) - Feb 3, 2016
P2, N=102, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2015 --> Jun 2016 Trial primary completion date: Feb 2017 --> Feb 2018
- ||||| Avastin (bevacizumab) / Roche
Enrollment closed, Trial primary completion date: A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma (clinicaltrials.gov) - Jan 4, 2016
P3, N=299, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Feb 2017 --> Feb 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Mar 2017
- NN1213 / Novo Nordisk
Trial primary completion date, Surgery: Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma (clinicaltrials.gov) - Dec 12, 2015
P=N/A, N=6, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Mar 2017 Trial primary completion date: Feb 2016 --> Feb 2017
- ||| Matulane (procarbazine hydrochloride) / Leadiant Biosci
Trial initiation date, Trial primary completion date: Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma (clinicaltrials.gov) - Nov 19, 2015
P2, N=90, Not yet recruiting, Sponsor: AIDS Malignancy Consortium
Trial primary completion date: Feb 2016 --> Feb 2017 Initiation date: Sep 2015 --> Dec 2015 | Trial primary completion date: Sep 2017 --> Dec 2017
- | NN1213 / Novo Nordisk, Matulane (procarbazine hydrochloride) / Leadiant Biosci
Trial completion: SWOG 9402: Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma (clinicaltrials.gov) - Nov 16, 2015
P3, N=299, Completed, Sponsor: Radiation Therapy Oncology Group
Initiation date: Sep 2015 --> Dec 2015 | Trial primary completion date: Sep 2017 --> Dec 2017 No longer recruiting --> Completed
- |||||| vocimagene amiretrorepvec/extended release flucytosine (DB107) / Denovo
Enrollment open: Toca5: The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma (clinicaltrials.gov) - Nov 9, 2015
P2/3, N=170, Recruiting, Sponsor: Tocagen Inc.
No longer recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment change, Trial termination, Trial primary completion date, Surgery: Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma (clinicaltrials.gov) - Oct 1, 2015
P2, N=30, Terminated, Sponsor: Children's Hospital of Philadelphia
Not yet recruiting --> Recruiting N=50 --> 30 | Recruiting --> Terminated | Trial primary completion date: Dec 2011 --> May 2011; The study was terminated prematurely due to slow accrual.
- | buparlisib (AN2025) / Adlai Nortye
Enrollment closed, Enrollment change, Trial primary completion date: Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - Sep 24, 2015
P1/2, N=35, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=50 --> 30 | Recruiting --> Terminated | Trial primary completion date: Dec 2011 --> May 2011; The study was terminated prematurely due to slow accrual. Recruiting --> Active, not recruiting | N=176 --> 35 | Trial primary completion date: Mar 2017 --> Dec 2015
- |||| NN1213 / Novo Nordisk
Trial primary completion date, Combination therapy: Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma (clinicaltrials.gov) - Sep 18, 2015
P3, N=549, Active, not recruiting, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting | N=176 --> 35 | Trial primary completion date: Mar 2017 --> Dec 2015 Trial primary completion date: Jul 2016 --> Dec 2015
- ||| Inlyta (axitinib) / Pfizer
Enrollment closed, Combination therapy, Monotherapy: AxiGII: A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma (clinicaltrials.gov) - Jul 2, 2015
P2, N=52, Active, not recruiting, Sponsor: Bart Neyns
Trial primary completion date: Jul 2016 --> Dec 2015 Recruiting --> Active, not recruiting
- lomustine / Generic mfg., temozolomide / Generic mfg.
Trial primary completion date, Combination therapy: CeTeG: Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients (clinicaltrials.gov) - Jun 11, 2015
P3, N=128, Active, not recruiting, Sponsor: University Hospital, Bonn
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2015 --> Nov 2015